Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DoH (Department of Health) consults on next NICE (UK National Institute for Clinical Excellence) assessment programme:

This article was originally published in Clinica

Executive Summary

Photodynamic therapy to treat age-related macular degeneration (AMD), hip resurfacing, ultrasonic central venous line ('c-line') detection and surgical procedures to treat morbid obesity are among the technologies that the UK's Department of Health plans to refer next to the National Institute for Clinical Excellence (NICE), following consultation with key stakeholders. Meanwhile, NICE has approved new appraisal guidelines. At this month's board meeting it also decided to strengthen its assessment capacity and establish an appeals committee.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT069976

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel